The leading biotech firm Gilead Sciences, Inc. announced to acquire germnay based MYR GmbH for approximately $1.4 billion. The acquisition will provide Hepcludex (bulevirtide), for the treatment of chronic HDV infection in adults.
Gilead focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV).
MYR has since launched Hepcludex in France, Germany and Austria,
Hepcludex is a first-in-class treatment for HDV that blocks viral entry into liver cells through binding to NTCP.
The major expansions and collaborations by Gilead Science are mentioned below:
Sep 2020: Gilead Sciences, Inc. announced a definitive agreement to acquire a New Jersey based company Immunomedics for approximately $21 billion. Immunomedics is a leading pharmaceutical company focusing on the development of antibody-drug conjugates for the treatment of cancer.
Aug 2020: Gilead Sciences, announced an expanded strategic collaboration with Tango Therapeutics to focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer.
March 2020: Gilead Sciences, Inc announced to acquire a clinical-stage immuno-oncology company Forty Seven Inc. for approximately $4.9 billion. The deal helps to add Forty Sevens investigational lead product candidate, magrolimab. The transaction will strengthen Gileads immuno-oncology research and development portfolio.
December 2019: Gilead Sciences, Inc. announced that Gilead Sciences K.K. and Eisai entered into an agreement for the distribution and co-promotion of filgotinib, an investigational, oral, selective JAK1 inhibitor, in Japan for the treatment of rheumatoid arthritis (RA).
About Gilead Sciences
Gilead Sciences, headquartered in Foster City, California, the USA, is a leading research-based biopharmaceutical company. The company develops and commercializes innovative medicines in areas of unmet medical need. It has more than 12,000 employees and has operations in approximately 35 countries globally.